Orchard Therapeutics at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Orchard Therapeutics brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on lentiviral gene therapy for blood stem cells. Topics include a risk-based way to characterise the manufacturing process and small molecules that make stem cells easier to transduce outside the body.

OrganizationESGCT 2026 Attendance
orchard-tx.com
Biotech
Develops lentiviral blood stem cell gene therapies, including an approved treatment for metachromatic leukodystrophy; part of Kyowa Kirin.
Poster
Wed Oct 28
1:30pm–3:30pm
A risk-based approach to process characterisation of a lentiviral manufacturing process
Lentiviral vectors / Integrative vectors
Poster
Thu Oct 29
2:00pm–4:00pm
Enhancing Lentiviral Transduction Efficiency in Haematopoietic Stem Cells ex vivo using Small Molecule Viral Sensitizers
Lentiviral vectors / Integrative vectors

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Orchard Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction